ALEXANDER LAZAR to TOR Serine-Threonine Kinases
This is a "connection" page, showing publications ALEXANDER LAZAR has written about TOR Serine-Threonine Kinases.
Connection Strength
0.501
-
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. Cancer Biol Ther. 2017 10 03; 18(10):816-826.
Score: 0.091
-
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst. 2016 12; 108(12).
Score: 0.084
-
Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2012 Aug; 11(8):1758-69.
Score: 0.064
-
Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res. 2012 Sep 01; 18(17):4633-45.
Score: 0.063
-
Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin Cancer Res. 2011 Sep 15; 17(18):5901-12.
Score: 0.059
-
Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. 2009 May; 8(5):1157-68.
Score: 0.051
-
Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients. Oncotarget. 2022; 13:521-533.
Score: 0.031
-
Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma. Acta Biomater. 2019 12; 100:38-51.
Score: 0.026
-
Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma. Oncotarget. 2014 Oct 15; 5(19):9065-78.
Score: 0.019
-
Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways. Expert Rev Mol Med. 2009 Oct 19; 11:e30.
Score: 0.013